Overview

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Status:
Completed
Trial end date:
2017-03-21
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of lenalidomide in patients with Adult T-cell Leukemia-lymphoma (ATL) who have previously received chemotherapy for ATL.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Lenalidomide
Thalidomide